Far Infrared Therapy Inhibits Vascular Endothelial Inflammation via the Induction of Heme Oxygenase-1

July 1, 2008

Abstract

Objective—Survival of arteriovenous fistulas (AVFs) in hemodialysis patients is associated with both far infrared (FIR) therapy and length polymorphisms of the heme oxygenase-1 (HO-1) promoter. In this study, we evaluated whether there is an interaction between FIR radiation and HO-1 in regulating vascular inflammation.

Methods and Results—Treatment of cultured human umbilical vein endothelial cells (ECs) with FIR radiation stimulated HO-1 protein, mRNA, and promoter activity. HO-1 induction was dependent on the activation of the antioxidant responsive element/NF-E2-related factor-2 complex, and was likely a consequence of heat stress. FIR radiation also inhibited tumor necrosis factor-α-mediated expression of E-selectin, vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, monocyte chemoattractant protein-1, interleukin-8, and the cytokine-mediated adhesion of monocytes to ECs. The anti-inflammatory action of FIR was mimicked by bilirubin, and was reversed by the HO inhibitor, tin protoporphyrin-IX, or by the selective knockdown of HO-1. Finally, the anti-inflammatory effect of FIR was also observed in patients undergoing hemodialysis.

Conclusions—These results demonstrate that FIR therapy exerts a potent anti-inflammatory effect via the induction of HO-1. The ability of FIR therapy to inhibit inflammation may play a critical role in preserving blood flow and patency of AVFs in hemodialysis patients.

-Arterioscler Thromb Vasc Biol. 2008 April ; 28(4): 739–745.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
May 23, 2025
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team.  Let’s explore how far-infrared therapy is transforming the future of vascular access—together.
May 23, 2025
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients. 
December 2, 2024
Meet FIRAPY at Booth i1115a!
More Posts